(Total Views: 193)
Posted On: 02/03/2021 3:00:08 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ). The letter informed Predictive Oncology that the company had regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the exchange’s listing rules. In October 2020, POAI had been notified by NASDAQ that it no longer met the organization’s minimum price bid requirement because it’s closing bid price per share had been below $1 for a period of 30 consecutive business days. The receipt of the most recent letter means that from Jan. 19, 2021, to Feb. 1, 2021, which covers the required last 10 consecutive business days, the closing bid price of Predictive Oncology’s common stock has been at $1 per share or greater, which means the company has regained compliance with the minimum bid price requirement. NASDAQ noted that it considers the matter now closed.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ). The letter informed Predictive Oncology that the company had regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the exchange’s listing rules. In October 2020, POAI had been notified by NASDAQ that it no longer met the organization’s minimum price bid requirement because it’s closing bid price per share had been below $1 for a period of 30 consecutive business days. The receipt of the most recent letter means that from Jan. 19, 2021, to Feb. 1, 2021, which covers the required last 10 consecutive business days, the closing bid price of Predictive Oncology’s common stock has been at $1 per share or greater, which means the company has regained compliance with the minimum bid price requirement. NASDAQ noted that it considers the matter now closed.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
